130 related articles for article (PubMed ID: 23200902)
1. Peroxynitrite--altered platelet mitochondria--a new link between inflammation and hemostasis.
Misztal T; Przesław K; Rusak T; Tomasiak M
Thromb Res; 2013 Jan; 131(1):e17-25. PubMed ID: 23200902
[TBL] [Abstract][Full Text] [Related]
2. Peroxynitrite may affect clot retraction in human blood through the inhibition of platelet mitochondrial energy production.
Misztal T; Rusak T; Tomasiak M
Thromb Res; 2014 Mar; 133(3):402-11. PubMed ID: 24388569
[TBL] [Abstract][Full Text] [Related]
3. Peroxynitrite may affect fibrinolysis via the reduction of platelet-related fibrinolysis resistance and alteration of clot structure.
Misztal T; Rusak T; Brańska-Januszewska J; Ostrowska H; Tomasiak M
Free Radic Biol Med; 2015 Dec; 89():533-47. PubMed ID: 26454084
[TBL] [Abstract][Full Text] [Related]
4. Clinically relevant HOCl concentrations reduce clot retraction rate via the inhibition of energy production in platelet mitochondria.
Misztal T; Rusak T; Tomasiak M
Free Radic Res; 2014 Dec; 48(12):1443-53. PubMed ID: 25236568
[TBL] [Abstract][Full Text] [Related]
5. Peroxynitrite can affect platelet responses by inhibiting energy production.
Rusak T; Tomasiak M; Ciborowski M
Acta Biochim Pol; 2006; 53(4):769-76. PubMed ID: 17068635
[TBL] [Abstract][Full Text] [Related]
6. Reduced clot retraction rate and altered platelet energy production in patients with asthma.
Tomasiak-Lozowska MM; Rusak T; Misztal T; Bodzenta-Lukaszyk A; Tomasiak M
J Asthma; 2016 Aug; 53(6):589-98. PubMed ID: 27145190
[TBL] [Abstract][Full Text] [Related]
7. The myeloperoxidase product, hypochlorous acid, reduces thrombus formation under flow and attenuates clot retraction and fibrinolysis in human blood.
Misztal T; Golaszewska A; Tomasiak-Lozowska MM; Iwanicka M; Marcinczyk N; Leszczynska A; Chabielska E; Rusak T
Free Radic Biol Med; 2019 Sep; 141():426-437. PubMed ID: 31279970
[TBL] [Abstract][Full Text] [Related]
8. Clot lysis time in platelet-rich plasma: method assessment, comparison with assays in platelet-free and platelet-poor plasmas, and response to tranexamic acid.
Panes O; Padilla O; Matus V; Sáez CG; Berkovits A; Pereira J; Mezzano D
Platelets; 2012; 23(1):36-44. PubMed ID: 21787173
[TBL] [Abstract][Full Text] [Related]
9. Nitric oxide and platelet energy metabolism.
Tomasiak M; Stelmach H; Rusak T; Wysocka J
Acta Biochim Pol; 2004; 51(3):789-803. PubMed ID: 15448739
[TBL] [Abstract][Full Text] [Related]
10. Rapid dissociation of platelet-rich fibrin clots in vitro by a combination of plasminogen activators and antiplatelet agents.
Lam SC; Dieter JP; Strebel LC; Taylor TM; Muscolino G; Feinberg H; Le Breton GC
J Pharmacol Exp Ther; 1991 Dec; 259(3):1371-8. PubMed ID: 1762085
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of rat platelet aggregation by mycalolide-B, a novel inhibitor of actin polymerization with a different mechanism of action from cytochalasin-D.
Sugidachi A; Ogawa T; Asai F; Saito S; Ozaki H; Fusetani N; Karaki H; Koike H
Thromb Haemost; 1998 Mar; 79(3):614-9. PubMed ID: 9531051
[TBL] [Abstract][Full Text] [Related]
12. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
[TBL] [Abstract][Full Text] [Related]
13. The effects of fibrinogen levels on thromboelastometric variables in the presence of thrombocytopenia.
Lang T; Johanning K; Metzler H; Piepenbrock S; Solomon C; Rahe-Meyer N; Tanaka KA
Anesth Analg; 2009 Mar; 108(3):751-8. PubMed ID: 19224779
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of cytochalasin B on platelet release, aggregation and contractility: evidence against a contractile mechanism for the release of platelet granular contents.
Kirkpatrick JP; McIntire LV; Moake JL; Cimo PL
Thromb Haemost; 1980 Feb; 42(5):1483-9. PubMed ID: 6892735
[TBL] [Abstract][Full Text] [Related]
15. In vitro inhibition of factor XIII retards clot formation, reduces clot firmness, and increases fibrinolytic effects in whole blood.
Jámbor C; Reul V; Schnider TW; Degiacomi P; Metzner H; Korte WC
Anesth Analg; 2009 Oct; 109(4):1023-8. PubMed ID: 19762725
[TBL] [Abstract][Full Text] [Related]
16. [Physiological and clinical significance of blood clot retraction (review of the literature)].
Iakunin GA
Lab Delo; 1984; (8):451-6. PubMed ID: 6207361
[No Abstract] [Full Text] [Related]
17. In vitro comparative study of hemostatic components in warfarin-treated and fibrinogen-deficient plasma.
Rumph B; Bolliger D; Narang N; Molinaro RJ; Levy JH; Szlam F; Tanaka KA
J Cardiothorac Vasc Anesth; 2010 Jun; 24(3):408-12. PubMed ID: 19819728
[TBL] [Abstract][Full Text] [Related]
18. The effect of fibrin clots and clot-bound thrombin on the development of platelet procoagulant activity.
Kumar R; Béguin S; Hemker HC
Thromb Haemost; 1995 Sep; 74(3):962-8. PubMed ID: 8571330
[TBL] [Abstract][Full Text] [Related]
19. Platelet microtubules in clot structure formation and contractile force generation: investigation of a controversy.
Jen CJ; McIntire LV
Thromb Haemost; 1986 Aug; 56(1):23-7. PubMed ID: 2877507
[TBL] [Abstract][Full Text] [Related]
20. Platelet-related fibrinolysis resistance in patients suffering from PV. Impact of clot retraction and isovolemic erythrocytapheresis.
Rusak T; Piszcz J; Misztal T; Brańska-Januszewska J; Tomasiak M
Thromb Res; 2014 Jul; 134(1):192-8. PubMed ID: 24824295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
